Company Overview and News


Add GLMD
to your dashboard

Headline News

ROTY Edition 1 Volume 69: BTD For Global Blood Therapeutics And Other Updates

2018-01-10 seekingalpha
After yesterday´s positive price action the ROTY model account is firmly in the green for the month of January (so far). (181-2)

ROTY Edition 1 Volume 67: Starting January On A Strong Note

2018-01-03 seekingalpha
ROTY had a solid December and January appears to be starting on a strong note as well. (107-1)

Jonathan Faison Positions For 2018: Faster FDA Approval, Emerging Sector In China Bode Well For Biotech Next Year

2017-12-20 seekingalpha
Despite recent doom and gloom talk that came as a result of the pullback in fall, it has still been a decent year. (482-1)

Galmed Looks To Trim Fat With 2018 Phase 2 Resolution

2017-11-30 seekingalpha
The company is engaged in two phase 2 clinical trials evaluating safety and efficacy of lead candidate Aramchol in NASH. (80-0)

ROTY Edition 1 Volume 52: Material Updates And Trades

2017-11-15 seekingalpha
Performance of the ROTY model account has suffered lately due to both continued weakness in the biotech sector as well as a couple losers that we cut recently. (15-0)

Galmed Pharmaceuticals' (GLMD) CEO Allen Baharaff on Q3 2017 Results - Earnings Call Transcript

2017-11-09 seekingalpha
Good day and welcome to the Galmed Pharmaceuticals Third Quarter 2017 Earnings Call. Today's call is being recorded.

Galmed Pharmaceuticals' (GLMD) CEO Allen Baharaff on Q2 2017 Results - Earnings Call Transcript

2017-07-31 seekingalpha
Good morning and welcome to the Galmed Pharmaceuticals Second Quarter 2017 Earnings Call. Before we begin, please note that we will be making certain forward-looking statements on today’s call, including those regarding financial results, statements and forecasts regarding anticipated timelines and expectations with respect to our regulatory and clinical development programs as well as other statements that relate to future events.

Biotech Forum Daily Digest: Dynavax Scores Huge Ad Comm Recommendation

2017-07-31 seekingalpha
Biotech fell some one percent last week as the sector continues to consolidate June large gains and there remains a dearth of new M&A activity.

Galmed Pharmaceuticals: Buy On Weakness

2017-07-26 seekingalpha
Data presented at EASL continued to indicate the significant potential of Aramchol in the NASH setting.

Galmed Pharmaceuticals (GLMD) Catches Eye: Stock Gains 15.7%

2017-07-25 zacks
Galmed Pharmaceuticals Ltd. (GLMD - Free Report) was a big mover last session, as the company saw its shares jump nearly 16% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend for the company as the stock is now trading above the volatile price range of $6.02 to $6.85 in the past one-month time frame.

NASH: KOL Insight [2017]

2017-07-05 prnewswire
LONDON, July 5, 2017 /PRNewswire/ -- Will novel therapies revolutionise the treatment of NASH? No drug therapies have been approved for patients with nonalcoholic steatohepatitis (NASH) but how is this set to change within the next five years? Allergan/Tobira's cenicriviroc and Gilead's selonsertib have entered the Phase III pipeline but how do they compare with other agents, Intercept's obeticholic acid and Genfit's elafibranor. (0-1)

Galmed Pharmaceuticals' (GLMD) CEO Allen Baharaff on Q1 2017 Results - Earnings Call Transcript

2017-05-15 seekingalpha
Good morning and welcome to the Galmed Pharmaceuticals First Quarter 2017 Earnings Call. Before we begin, please note that Galmed will be making certain forward-looking statements on today’s call, including those regarding financial results, statements, forecasts regarding anticipated timelines and expectations with respect to regulatory and clinical development programs as well as other statements that relate to future events.

NASH: The next untapped pharma market gives investors many options

2017-04-24 reuters
Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020. (0-1)

3 Things In Biotech You Should Learn Today: April 24, 2017

2017-04-24 seekingalpha
Welcome to another edition of "3 Things in Biotech You Should Learn Today," a digest covering recent material events in the world of pharmaceuticals and biotechnology. Today, we're fidgeting between some coverage in oncology and liver disease, and it's all good news! I dig it.

CUSIP: M47238106